Paradigm Biopharmaceuticals Ltd
ASX:PAR

Watchlist Manager
Paradigm Biopharmaceuticals Ltd Logo
Paradigm Biopharmaceuticals Ltd
ASX:PAR
Watchlist
Price: 0.285 AUD -5%
Market Cap: 111m AUD

Relative Value

The Relative Value of one PAR stock under the Base Case scenario is 0.275 AUD. Compared to the current market price of 0.285 AUD, Paradigm Biopharmaceuticals Ltd is Overvalued by 4%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

PAR Relative Value
Base Case
0.275 AUD
Overvaluation 4%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
77
vs Industry
28
Median 3Y
27.2
Median 5Y
38.5
Industry
6.9
Forward
36.6
vs History
vs Industry
Median 3Y
-5.9
Median 5Y
-8.7
Industry
22.4
Forward
-4
vs History
vs Industry
Median 3Y
-3.5
Median 5Y
-9.3
Industry
19.1
vs History
vs Industry
Median 3Y
-3.5
Median 5Y
-9.3
Industry
23.2
vs History
82
vs Industry
22
Median 3Y
4.4
Median 5Y
5.6
Industry
2.5
vs History
74
vs Industry
25
Median 3Y
22.4
Median 5Y
33.5
Industry
7.5
Forward
28.5
vs History
50
vs Industry
23
Median 3Y
22.5
Median 5Y
17.3
Industry
8.9
vs History
vs Industry
Median 3Y
-4.7
Median 5Y
-7.1
Industry
4
Forward
-1.8
vs History
vs Industry
Median 3Y
-4.7
Median 5Y
-7.1
Industry
3.7
Forward
-1.8
vs History
vs Industry
Median 3Y
-2.7
Median 5Y
-8.1
Industry
4.5
vs History
vs Industry
Median 3Y
-2.7
Median 5Y
-8.1
Industry
3.4
vs History
85
vs Industry
17
Median 3Y
28.7
Median 5Y
47.5
Industry
4.6

Multiples Across Competitors

PAR Competitors Multiples
Paradigm Biopharmaceuticals Ltd Competitors

Market Cap P/S P/E EV/EBITDA EV/EBIT
AU
Paradigm Biopharmaceuticals Ltd
ASX:PAR
111m AUD 19.5 -7.1 -5.5 -5.5
FR
Pharnext SCA
OTC:PNEXF
6T USD 35 162 939 -167 124.2 -202 942.1 -200 626.3
US
Abbvie Inc
NYSE:ABBV
346.1B USD 6.1 81.7 16.1 24.3
US
Amgen Inc
NASDAQ:AMGN
150.4B USD 4.5 36.8 15.2 26.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
128.5B USD 11.7 -240 26.3 27.5
US
Gilead Sciences Inc
NASDAQ:GILD
128.1B USD 4.5 266.9 10.5 13.2
US
Epizyme Inc
F:EPE
94.1B EUR 2 003.5 -511.2 -556.7 -541.9
AU
CSL Ltd
ASX:CSL
124.3B AUD 5.3 29.2 17.9 22.4
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
66.2B USD 4.7 15 9.4 10.5
US
Seagen Inc
F:SGT
39.3B EUR 19.3 -59.2 -63.7 -57.5
NL
argenx SE
XBRU:ARGX
35.1B EUR 18.1 47.6 -2 688.4 -1 802.4
P/S Multiple
Revenue Growth P/S to Growth
AU
Paradigm Biopharmaceuticals Ltd
ASX:PAR
Average P/S: 3 196 821.5
19.5
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
35 162 939
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.1
7%
0.9
US
Amgen Inc
NASDAQ:AMGN
4.5
4%
1.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
11.7
10%
1.2
US
Gilead Sciences Inc
NASDAQ:GILD
4.5
3%
1.5
US
E
Epizyme Inc
F:EPE
2 003.5
N/A N/A
AU
CSL Ltd
ASX:CSL
5.3
7%
0.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
4.7
6%
0.8
US
S
Seagen Inc
F:SGT
19.3
30%
0.6
NL
argenx SE
XBRU:ARGX
18.1
39%
0.5
P/E Multiple
Earnings Growth PEG
AU
Paradigm Biopharmaceuticals Ltd
ASX:PAR
Average P/E: 79.5
Negative Multiple: -7.1
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -167 124.2 N/A N/A
US
Abbvie Inc
NYSE:ABBV
81.7
87%
0.9
US
Amgen Inc
NASDAQ:AMGN
36.8
44%
0.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -240 N/A N/A
US
Gilead Sciences Inc
NASDAQ:GILD
266.9
187%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -511.2 N/A N/A
AU
CSL Ltd
ASX:CSL
29.2
16%
1.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15
10%
1.5
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.2 N/A N/A
NL
argenx SE
XBRU:ARGX
47.6
28%
1.7
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
AU
Paradigm Biopharmaceuticals Ltd
ASX:PAR
Average EV/EBITDA: 15.9
Negative Multiple: -5.5
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -202 942.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.1
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
15.2
17%
0.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.3
18%
1.5
US
Gilead Sciences Inc
NASDAQ:GILD
10.5
7%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -556.7 N/A N/A
AU
CSL Ltd
ASX:CSL
17.9
11%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
9.4
14%
0.7
US
S
Seagen Inc
F:SGT
Negative Multiple: -63.7 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -2 688.4 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
AU
Paradigm Biopharmaceuticals Ltd
ASX:PAR
Average EV/EBIT: 20.8
Negative Multiple: -5.5
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -200 626.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
24.3
29%
0.8
US
Amgen Inc
NASDAQ:AMGN
26.9
31%
0.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
27.5
17%
1.6
US
Gilead Sciences Inc
NASDAQ:GILD
13.2
11%
1.2
US
E
Epizyme Inc
F:EPE
Negative Multiple: -541.9 N/A N/A
AU
CSL Ltd
ASX:CSL
22.4
14%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
10.5
13%
0.8
US
S
Seagen Inc
F:SGT
Negative Multiple: -57.5 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -1 802.4 N/A N/A